Treatment of low-risk myelodysplastic syndromes with high-dose daily oral cholecalciferol (2000-4000 IU vitamin D3) [1]

Leukemia

Volumn 21, Issue 5, 2007, Pages 1089-1092

  Molnar I ^a   Stark, N ^a   Lovato, J ^a   Powell, B L ^a   Cruz, J ^a   Hurd, D D ^a   Mathieu, J S ^b   Chen, T C ^b   Holick, M F ^b   Cambra, S ^a   McQuellon, R P ^a   Schwartz, G G ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; AMIFOSTINE; ARSENIC TRIOXIDE; AZACITIDINE; CALCIUM; CIPROFLOXACIN; COLECALCIFEROL; CREATININE; CYCLOSPORIN; DANAZOL; DEXAMETHASONE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PENTOXIFYLLINE; PHOSPHORUS; THALIDOMIDE; THYMOCYTE ANTIBODY; TOPOTECAN;

ADULT; AGED; BONE MARROW BIOPSY; CALCIUM BLOOD LEVEL; CANCER RISK; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; KARYOTYPE; LETTER; MEDICATION ERROR; MORTALITY; MYELODYSPLASTIC SYNDROME; NAUSEA; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROGNOSIS; PSORIASIS; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; REFERENCE VALUE; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE TRANSFUSION; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 34247644442     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404601     Document Type: Letter

References (8)

1. 3. Proc Natl Acad Sci USA 1981; 78 4990-4995.
2. Mellibovsky L, Diez A, Perez-Vila E, Serrano S, Nacher M, Aubia J et al. Vitamin D treatment in myelodysplastic syndromes. Br J Haematol 1998; 100: 516-520.
3. Chen TC, Turner AK, Holick MF. Methods for the determination of the circulating concentration of 25-hydroxyvitamin D. J Nutr Biochem 1990; 1: 315-319.
4. Brucker PS, Yost K, Cashy J, Webster K, Cella D. General population and cancer patient norms for the Functional Assessment of Cancer Therapy - General (FACT-G). Eval Health Prof 2005; 28: 192-211.
5. Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002; 24: 547-561.
6. Jorde R, Waterloo K, Saleh F, Haug E, Svartherg J. Neuropsychological function in relation to serum parathyroid hormone and serum 25-hydroxyvitamin D levels. J Neurol 2006; 253: 464-470.
7. Lansdowne ATG, Provost SC. Vitamin D3 enhances mood in healthy subjects during winter. Psychopharmacology 1998; 135: 319.
8. Vieth R, Kimball S, Hu A, Walfish PG. Randomized comparison of the effects of the vitamin D3 adequate intake versus 100mcg (4000 IU) per day on biochemical responses and the wellbeing of patients. Nutr J 2004; 3: 8.